Exact Sciences

Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.

The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.

The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.

The company said test volume rose 87 percent to 186,000 during the quarter.

The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.